Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kei-Lai Fong"'
Autor:
Kathryn W. Woodburn, Susan D. Wilson, Kei-lai Fong, Peter J. Schatz, Thomas Ferrell, Charles B. Spainhour, Daniel Norton
Publikováno v:
Haematologica, Vol 93, Iss 9 (2008)
Hematide is a synthetic peptide-based, pegylated erythropoiesis stimulating agent in clinical development for treatment of anemia. To support chronic clinical dosing requirements, a 9-month repeat dose IV monkey safety study was undertaken. Animals r
Externí odkaz:
https://doaj.org/article/27d4a681f09545cfafa1e77b0afce10b
Autor:
Susan D. Wilson, Kei-lai Fong, Yuu Moriya, Kathryn W. Woodburn, Paul Strzemienski, Eric Solon, Yoshihiko Tagawa, Steven Sloneker
Publikováno v:
Drug Metabolism and Disposition. 41:774-784
Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics
Autor:
Susan D. Wilson, Randall J. Press, Christopher P. Holmes, Yuu Moriya, Yoshihiko Tagawa, Kei-lai Fong, Kathryn W. Woodburn
Publikováno v:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
The pharmacokinetics (PK) (absorption, distribution, metabolism, excretion) of peginesatide, a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent (ESA), was evaluated in rats. The PK profile was evaluated at 0.1-5 m
Autor:
Dorota Cedzik, Zhe-ming Gu, Oscar L. Laskin, Anfan Wu, Lori Capone, Sekhar Surapaneni, Peter H. Schafer, Gondi Kumar, Kei-Lai Fong, Dennis Heller, Matthew Hoffmann, Hao Feng
Publikováno v:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
Apremilast is a novel, orally available small molecule that specifically inhibits PDE4 and thus modulates multiple pro- and anti-inflammatory mediators, and is currently under clinical development for the treatment of psoriasis and psoriatic arthriti
Autor:
Thomas Ferrell, Kathryn W. Woodburn, Daniel Norton, Susan D. Wilson, Charles B. Spainhour, Kei-lai Fong, Peter J. Schatz
Publikováno v:
Haematologica. 93:1376-1379
Hematide is a synthetic peptide-based, pegylated erythropoiesis stimulating agent in clinical development for treatment of anemia. To support chronic clinical dosing requirements, a 9-month repeat dose IV monkey safety study was undertaken. Animals r
Autor:
Thomas Ferrell, Peter J. Schatz, Kathryn W. Woodburn, Daniel Norton, Susan D. Wilson, Charles B. Spainhour, Kei-lai Fong
Publikováno v:
Drug and Chemical Toxicology. 31:229-244
The pharmacology, toxicokinetics, and safety of Hematide, a synthetic peptidic erythropoiesis-stimulating agent (ESA), were characterized. Hematide was given intravenously (0, 0.5, 5, and 50 mg/kg) weekly for five weeks with a 6- (rat) and 12-week (m
Autor:
Kathryn W. Woodburn, Peter J. Schatz, Sudhir A. Shah, Valentine O Wagner, Ramadevi Gudi, Susan D. Wilson, Ljubica Krsmanovic, Kei-lai Fong, Madhav Paranjpe
Publikováno v:
Drug and chemical toxicology. 34(3)
Peginesatide is a PEGylated, investigational, peptide-based erythropoiesis-stimulating agent (ESA) that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Clinical use of peginesatide
Autor:
Kei-lai Fong, Alan M. Hoberman, Peter J. Schatz, Kathryn W. Woodburn, Elise M. Lewis, Susan D. Wilson
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology.
BACKGROUND: Aperi- and postnatal reproduction toxicity study was conducted in rats treated with Hematide, a synthetic PEGylated peptidic erythropoiesis stimulating agent (ESA). METHODS: Hematide, at IV doses of 0, 0.5, 3, and 15 mg/kg, was administer
Publikováno v:
Drug and chemical toxicology. 33(1)
The subchronic toxicity of Hematide™, a synthetic PEGylated peptidic erythropoiesis-stimulating agent (ESA), was evaluated in CD-1 mice at intravenous doses of 0, 1, 5, 25, and 125 mg/kg administered once every 3 weeks for 3 months. Hematide displa
Autor:
Noriyuki Okada, Karsten Roth, Naohisa Tomosugi, Adrian Zugravu, Nicanor Vega, Marina Shestakova, Alain Guerin, Josep M. Campistol, Gabriel Mircescu, M. Laville, P. Lang, Cristina Capusa, Serhat Karadag, Aritoshi Kida, Marc Froissart, Mourad Farouk, M. Fellous, Hyun Woo Kim, Yasemin Doventas, Yasushi Shimonaka, Hiroaki Kawabata, Akira Suzuki, Petronila Rocha-Pereira, Antonio Pérez, Stephan Heidenreich, Christopher Holmes, Savas Ozturk, François Vrtovsnik, Emel Tatli, Ana Stanciu, Agustín Carreño, Kosaku Nitta, Liliane Garneata, Masami Bessho, Kei-Lai Fong, Salvatore Di Giulio, Francesco Locatelli, Ricardo Correa-Rotter, Zeki Aydin, Eun Hee Jang, Rumeyza Kazancioglu, Marite Ode, Michal Mysliwiec, V. Esnault, Jacek S. Malyszko, J.-P. Ryckelynck, Lucile Mercadal, Gabriel Mirescu, Manuel Arias, Ligia Petrescu, José M. Morales, Minoru Furuta, G. Choukroun, Takuya Uehata, Alice Santos-Silva, Antonio Franco, Roland Schäfer, Luís Belo, Jan Galle, Kathleen Claes, M.J. Camba, M. Bicho, Takahiro Kuragano, Yoshinaga Otaki, Yolanta Malyszko, Nicole Casadevall, Futoshi Nisihara, Jean-Philippe Haymann, Steven Sloneker, B. Knebelman, Martin Flamant, Rie Kitamura, Masashi Suzuki, István Kiss, Ian Bridges, Piotr Kozminski, S. Bea, Minoru Ando, José Luis Górriz Teruel, Abdullah Sumnu, Walter H. Hörl, Jean-Jacques Boffa, Sami Uzun, Macit Koldas, David Goldsmith, Kakuya Niihata, Paul Strzemienski, D. Sanchez-Guisande, A. Martínez Castelao, Tatsuya Shoji, José Portolés, Pierre-Yves Martin, E. Legrand, Ewa Koc-Zorawska, Claudio Mori, Masaki Hara, V. Miranda, Gilbert Deray, Takeshi Nakanishi, Frank Leistikow, Meltem Gursu, M. Sameiro-Faria, E. Espinel, Hiroshi Nonoguchi, Chris Winearls, L. Pallardó, Ken Tsuchiya, P. Bataille, J. Calls, Mika Sonoda, C. Afonso, Kathryn Woodburn, Yusuke Sakaguchi, Aleix Cases, Yoshiharu Tsubakihara, Simona Stancu, Janet Addison, Mana Yahiro, C. Marinho, Nomy Levin-Iaina, Daniell Mitchell, Marie Metzger, Elísio Costa, Eric Solon, G. Fernández-Fresnedo, Liliana Viasu, Bénédicte Stengel
Publikováno v:
Clinical Kidney Journal. 4:4.s2.32-4.s2.32